Antirotinib Hydrochloride Plus Whole Brain Radiotherapy for Small Cell Lung Cancer With Brain Metastases
Launched by CANCER INSTITUTE AND HOSPITAL, CHINESE ACADEMY OF MEDICAL SCIENCES · Sep 22, 2024
Trial Information
Current as of June 21, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new treatment approach for patients with small cell lung cancer that has spread to the brain, known as brain metastases. The researchers want to find out if combining a medication called antirotinib hydrochloride with a type of radiation therapy called whole brain radiotherapy can be effective and safe for these patients.
To be eligible for this trial, participants need to have a confirmed diagnosis of small cell lung cancer and must have completed at least four cycles of initial chemotherapy. They should expect to live for more than three months and have no more than ten brain metastases. If patients meet these criteria, they may have the opportunity to take part in this study, which is currently active but not recruiting new participants. Those who join will receive the combined treatment and will be monitored for how well it works and any side effects. It's important for potential participants to know that certain health conditions or previous treatments may prevent them from joining.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Small cell lung cancer confirmed by pathology, completion of at least 4 cycles of first-line chemotherapy, and measurable disease according to RECIST criteria.
- • 2. The expected survival time is more than 3 months.
- • 3. Intracranial metastases ≤10.
- • 4. Adequate organ and bone marrow function.
- Exclusion Criteria:
- • 1. Patients who have used antiangiogenic drugs within the previous 1 month.
- • 2. Non-small cell lung cancer (including small cell carcinoma and non-small cell carcinoma mixed lung cancer).
- • 3. Small cell lung cancer with hilar invasion or hemoptysis.
- • 4. Patients with intracranial acute, subacute cerebral infarction, intracranial lesions acute, subacute hemorrhage.
- • 5. An unresolved acute toxic reaction period higher than grade 2 of CTC-AE(4.0) due to any prior treatment.
- • 6. Advanced patients with severe symptoms, tumors that have spread to the internal organs, and a short-term risk of life-threatening complications.
- • 7. Patients with life-threatening conditions of other severe and/or uncontrolled diseases.
About Cancer Institute And Hospital, Chinese Academy Of Medical Sciences
The Cancer Institute and Hospital of the Chinese Academy of Medical Sciences is a leading research and treatment center dedicated to advancing cancer care through innovative clinical trials and comprehensive patient services. As a prominent institution in oncology, it focuses on integrating cutting-edge research with clinical practice, fostering collaborations that enhance the understanding and treatment of various cancer types. The institute is committed to improving patient outcomes by exploring novel therapies, optimizing treatment protocols, and contributing to the global fight against cancer through rigorous scientific investigation and evidence-based practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Lei Deng, MD
Study Chair
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported